Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 72

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 72
---
 totaled $987 thousand for the year ended December 31, 2023, representing an increase of $551 thousand, or 126.4%, compared to $436
thousand for the year ended December 31, 2022.

Liquidity

To date, the Company has not generated any
revenues from its current operations, incurred losses, and therefore is dependent upon external sources for financing its operations.
As of March 31, 2025, the Company had an accumulated deficit of $12,147 thousands. To support its operations and advance its development
programs, the Company intends to continue securing investments. Management anticipates that additional capital will be necessary to fund
its ongoing R&D activities and to explore opportunities for acquiring healthcare or healthcare-related technologies. However, there
are currently no binding commitments for further investment, and there can be no assurance that the Company will secure the required
capital on commercially reasonable terms, or at all.

If sufficient investment cannot be obtained,
the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain development programs. Despite
these potential challenges, management and the board of directors believe that the Company’s existing financial resources will
be sufficient to sustain its planned operations for at least the next twelve months.

The consolidated financial statements do not
include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of
liabilities that might be necessary should the Company be unable to continue as a going concern.

<div align='center'>42</div>

Between April and December 2023, the Company received
funds in the aggregate amount of $4,631.25 thousands from qualified investors subscribing into private placement units of the Company’s
securities, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2) shares of the
Company’s common stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s Common
Stock exercisable December 31, 2026, at a per share exercise price of $2.40. The price per Unit is $3.20. In consideration thereof, the
private placement investors were issued an aggregate of 2,894,532 of the Company’s Common Stock and warrants to purchase an additional
1,447,266 shares of Common stock.

At present, no warrants have been exercised. Based
on our current plans, we believe that with the net proceeds of our private placement